Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03551626
Title Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

skin melanoma

Therapies

Dabrafenib + Trametinib

Age Groups: adult | senior
Covered Countries CAN

Additional content available in CKB BOOST